Also, we have recently characterized a suppressive role of LECT2 in non-small cell lung cancer (NSCLC) progression via antagonizing c-Met and epidermal growth factor receptor (EGFR) [23]. This evidence concerns the gene MET and non-small cell lung carcinoma.